Drug updated on 3/28/2024
Dosage Form | Tablet (oral; 10 mg, 25 mg, 50 mg); PD Tablet for suspension (oral; 5 mg) |
Drug Class | HIV-1 integrase strand transfer inhibitor (INSTI) |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Tivicay and Tivicay PD are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults (treatment-naïve or -experienced) and in pediatric patients (treatment-naïve or -experienced but INSTI- naïve) aged at least 4 weeks and weighing at least 3 kg.
- Tivicay is indicated in combination with rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Tivicay (dolutegravir) Prescribing Information. | 2022 | ViiV Healthcare, Research Triangle Park, NC |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
EACS Guidelines. | 2023 | European AIDS Clinical Society |
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. | 2023 | NIH |
Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. | 2022 | NIH |
NYSDOH AIDS Institute HIV Clinical Guideline. | 2022 | New York State Department of Health AIDS Institute |
European AIDS clinical society guidelines v10.1 October 2020. | 2020 | European AIDS Clinical Society |